POTASSIUM ACETATE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for POTASSIUM ACETATE (POTASSIUM ACETATE).

How it works

Potassium acetate provides potassium ions, which are essential for maintaining intracellular ionic balance, nerve conduction, muscle contraction, and acid-base equilibrium. It acts as a potassium replenisher and can also be used to alkalinize urine by converting to bicarbonate.

What the body does with it

Metabolism	Potassium acetate is metabolized via the Krebs cycle to yield bicarbonate, primarily in the liver and kidneys, providing an alkalinizing effect.
Excretion	Primarily renal (>90%) as potassium ions; minimal biliary/fecal.
Half-life	Not applicable as potassium is not eliminated by first-order kinetics; plasma concentration reflects body stores and renal function.
Protein binding	Negligible (<5%); not significantly protein-bound.
Volume of Distribution	Approximately 0.5-0.7 L/kg; primarily intracellular distribution.
Bioavailability	Oral: 80-90% (absorbed from GI tract); intravenous: 100%.
Onset of Action	Intravenous: immediate upon infusion; oral: within 30-60 minutes.
Duration of Action	Duration depends on dose, administration rate, and renal function; typically 2-4 hours after IV bolus, longer with continuous infusion.

Classification & Brands

Dosing & administration

Intravenous, 10-20 mEq/h, maximum infusion rate 20 mEq/h, not to exceed 150 mEq/day.

Dosage form	INJECTABLE
Renal impairment	GFR 30-60 mL/min: consider 50% dose reduction; GFR <30 mL/min: contraindicated or use with extreme caution, monitor potassium levels closely.
Liver impairment	No specific adjustment recommended; monitor potassium levels due to risk of hyperkalemia in hepatic impairment.
Pediatric use	Intravenous, 0.5-1 mEq/kg/dose, maximum infusion rate 0.5 mEq/kg/h, not to exceed 3 mEq/kg/day.
Geriatric use	Start at lower end of adult dosing (10 mEq/h), monitor renal function and potassium levels, adjust according to renal function.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for POTASSIUM ACETATE (POTASSIUM ACETATE).

Breastfeeding

Potassium is a normal constituent of breast milk. Exogenous potassium acetate administration does not significantly increase milk potassium levels. M/P ratio is not applicable as potassium is endogenous. Generally considered compatible with breastfeeding, but maternal serum potassium should be monitored to avoid extreme deviations.

Teratogenic Risk

Potassium acetate is an electrolyte used for potassium repletion. No specific teratogenic effects are documented; however, potassium imbalance (hyperkalemia or hypokalemia) may affect fetal cardiac function. Use during pregnancy requires careful monitoring to maintain maternal serum potassium within the normal range, as maternal hypokalemia or hyperkalemia can cause fetal arrhythmias or other complications. No trimester-specific risks are established.

Warnings & precautions

■ FDA Black Box Warning

Potassium acetate injections should be diluted and administered slowly to avoid hyperkalemia and cardiac arrest. Rapid or concentrated infusion can be fatal.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hyperkalemia","Severe renal failure with oliguria or anuria","Addison's disease","Adynamic ileus or mechanical obstruction","Concurrent use of potassium-sparing diuretics (e.g., spironolactone, amiloride)","Untreated metabolic acidosis"]

Clinical Precautions

Precautions

["Risk of hyperkalemia, especially in renal impairment","Cardiac arrhythmias and arrest if administered too rapidly or in concentrated form","Use with caution in patients with cardiac disease, metabolic acidosis, or those receiving potassium-sparing diuretics","Monitor serum potassium, ECG, and renal function during therapy","Extravasation risk with peripheral IV administration"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

POTASSIUM ACETATE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for POTASSIUM ACETATE (POTASSIUM ACETATE).

How it works

What the body does with it

Metabolism	Potassium acetate is metabolized via the Krebs cycle to yield bicarbonate, primarily in the liver and kidneys, providing an alkalinizing effect.
Excretion	Primarily renal (>90%) as potassium ions; minimal biliary/fecal.
Half-life	Not applicable as potassium is not eliminated by first-order kinetics; plasma concentration reflects body stores and renal function.
Protein binding	Negligible (<5%); not significantly protein-bound.
Volume of Distribution	Approximately 0.5-0.7 L/kg; primarily intracellular distribution.
Bioavailability	Oral: 80-90% (absorbed from GI tract); intravenous: 100%.
Onset of Action	Intravenous: immediate upon infusion; oral: within 30-60 minutes.
Duration of Action	Duration depends on dose, administration rate, and renal function; typically 2-4 hours after IV bolus, longer with continuous infusion.

Classification & Brands

Dosing & administration

Intravenous, 10-20 mEq/h, maximum infusion rate 20 mEq/h, not to exceed 150 mEq/day.

Dosage form	INJECTABLE
Renal impairment	GFR 30-60 mL/min: consider 50% dose reduction; GFR <30 mL/min: contraindicated or use with extreme caution, monitor potassium levels closely.
Liver impairment	No specific adjustment recommended; monitor potassium levels due to risk of hyperkalemia in hepatic impairment.
Pediatric use	Intravenous, 0.5-1 mEq/kg/dose, maximum infusion rate 0.5 mEq/kg/h, not to exceed 3 mEq/kg/day.
Geriatric use	Start at lower end of adult dosing (10 mEq/h), monitor renal function and potassium levels, adjust according to renal function.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for POTASSIUM ACETATE (POTASSIUM ACETATE).

Breastfeeding

Teratogenic Risk

Warnings & precautions

■ FDA Black Box Warning

Potassium acetate injections should be diluted and administered slowly to avoid hyperkalemia and cardiac arrest. Rapid or concentrated infusion can be fatal.